Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04228978 (PROmote Weight Loss in Obese Peripheral Artery Disease), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Eric ReynoldsDepartment of Biostatistics and Data Science Wake Forest University School of Medicine Winston-Salem NC.
Cynthia L StoweDepartment of Biostatistics and Data Science Wake Forest University School of Medicine Winston-Salem NC.ORCID 0000-0002-1887-3294
Robert SufitFeinberg School of Medicine Northwestern University Chicago IL.ORCID 0000-0001-8827-2753
Linda Van HornFeinberg School of Medicine Northwestern University Chicago IL.ORCID 0000-0002-1362-5806
Michael P WalkupDepartment of Health and Exercise Science Wake Forest University Winston-Salem NC.
Walter T AmbrosiusDepartment of Biostatistics and Data Science Wake Forest University School of Medicine Winston-Salem NC.
Mary M McDermottFeinberg School of Medicine Northwestern University Chicago IL.ORCID 0000-0002-3724-7619
Wake Forest University · USNorthwestern University · USUniversity of Minnesota · USNational Institutes of Health · USUniversity of Chicago · USUniversity of Florida · USUniversity of Maryland, Baltimore · USUniversity of Tennessee at Knoxville · US
Funding
ConProject-006UH3HL141729 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCDERMOTT, MARY MCGRAE · 2020 to 2025
$3.1M
University of MN Building Interdisciplinary Research Careers in Women's HealthK12AR084223 · NIAMS · UNIVERSITY OF MINNESOTA · PI SHARON S ALLEN, Kristen Patricia Mark · 2023 to 2026
$2.2M
2/2 PROmote weight loss in obese PAD patients to preVEnt mobility loss: The PROVE Trial--DCCU24HL141732 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI AMBROSIUS, WALTER T · 2019 to 2025
Background Overweight and obesity are associated with adverse functional outcomes in people with peripheral artery disease (PAD). The effects of weight loss in people with overweight/obesity and PAD are unknown. Methods The PROVE (Promote Weight Loss in Obese PAD Patients to Prevent Mobility Loss) Trial is a multicentered randomized clinical trial with the primary aim of testing whether a behavioral intervention designed to help participants with PAD lose weight and walk for exercise improves 6-minute walk distance at 12-month follow-up, compared with walking exercise alone. A total of 212 participants with PAD and body mass index ≥25 kg/m
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Study Design, Rationale, and Methodology for Promote Weight Loss in Patients With Peripheral Artery Disease Who Also Have Obesity: The PROVE Trial. · full record | OpenQuestion